Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03580694 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Program reprioritization

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: REGN4659
DRUG: Cemiplimab

Sponsor

Regeneron Pharmaceuticals